InSilico Medicine (HKG:3696) is considering listing in Abu Dhabi less than a year after going public in Hong Kong, Bloomberg News reported Tuesday.
The Boston-based biotechnology firm has held preliminary discussions to list shares on the Abu Dhabi Securities Exchange as early as this year, the report said, citing people familiar with the matter.
InSilico Medicine was listed in Hong Kong in December 2025, raising HK$2.28 billion from its IPO. The Tencent Holdings-backed (HKG:0700) drug discovery company had a stellar trading debut with shares closing 25% higher than their IPO price of HK$24.05 in their first day of trading.
Insilico has yet to respond to' request for comment at press time.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)